The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.

INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.

PD-(L)1 x VEGF developments coinciding with ASCO overshadowed the conference proper.

Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.

BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.

LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.

Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.

Evopoint reveals intriguing but opaque first-in-human data for XNW27011.

Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.